OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
W. Kimryn Rathmell, R. Bryan Rumble, Peter J. Van Veldhuizen, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 25, pp. 2957-2995
Open Access | Times Cited: 189
W. Kimryn Rathmell, R. Bryan Rumble, Peter J. Van Veldhuizen, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 25, pp. 2957-2995
Open Access | Times Cited: 189
Showing 1-25 of 189 citing articles:
Treatment Landscape of Renal Cell Carcinoma
Yu‐Wei Chen, Luke Wang, Justine Panian, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 12, pp. 1889-1916
Open Access | Times Cited: 37
Yu‐Wei Chen, Luke Wang, Justine Panian, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 12, pp. 1889-1916
Open Access | Times Cited: 37
Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance
Sonia Mazumder, Paul J. Higgins, Rohan Samarakoon
Cancers (2023) Vol. 15, Iss. 4, pp. 1316-1316
Open Access | Times Cited: 36
Sonia Mazumder, Paul J. Higgins, Rohan Samarakoon
Cancers (2023) Vol. 15, Iss. 4, pp. 1316-1316
Open Access | Times Cited: 36
Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus
Shawn Dason, Jahan Mohebali, Michael L. Blute, et al.
Urologic Clinics of North America (2023) Vol. 50, Iss. 2, pp. 261-284
Closed Access | Times Cited: 29
Shawn Dason, Jahan Mohebali, Michael L. Blute, et al.
Urologic Clinics of North America (2023) Vol. 50, Iss. 2, pp. 261-284
Closed Access | Times Cited: 29
Combination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the PI3K-AKT signaling pathway
Junfeng Hao, Qiguang Chen, Yongmin Feng, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 4
Open Access | Times Cited: 23
Junfeng Hao, Qiguang Chen, Yongmin Feng, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 4
Open Access | Times Cited: 23
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
Leonard J. Appleman, Se Eun Kim, Wayne Harris, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 17, pp. 2061-2070
Closed Access | Times Cited: 13
Leonard J. Appleman, Se Eun Kim, Wayne Harris, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 17, pp. 2061-2070
Closed Access | Times Cited: 13
Advances in the management of renal cell carcinoma
Luisa M. Cardenas, Samantha Sigurdson, Christopher J.D. Wallis, et al.
Canadian Medical Association Journal (2024) Vol. 196, Iss. 7, pp. E235-E240
Open Access | Times Cited: 10
Luisa M. Cardenas, Samantha Sigurdson, Christopher J.D. Wallis, et al.
Canadian Medical Association Journal (2024) Vol. 196, Iss. 7, pp. E235-E240
Open Access | Times Cited: 10
Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study
Laurence Albigès, Marine Gross‐Goupil, Philippe Barthélémy, et al.
European Urology Oncology (2025)
Closed Access | Times Cited: 1
Laurence Albigès, Marine Gross‐Goupil, Philippe Barthélémy, et al.
European Urology Oncology (2025)
Closed Access | Times Cited: 1
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Viktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 21
Viktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 21
State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma
Shawn Dason, Kristine Peregrino Lacuna, Raquibul Hannan, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 20
Shawn Dason, Kristine Peregrino Lacuna, Raquibul Hannan, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 20
Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial
Zuzana Bielčiková, Jan Štursa, Ľudmila Křížová, et al.
EClinicalMedicine (2023) Vol. 57, pp. 101873-101873
Open Access | Times Cited: 18
Zuzana Bielčiková, Jan Štursa, Ľudmila Křížová, et al.
EClinicalMedicine (2023) Vol. 57, pp. 101873-101873
Open Access | Times Cited: 18
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
Regina Barragán-Carrillo, Eddy Saad, Renee-Maria Saliby, et al.
European Urology (2024)
Closed Access | Times Cited: 7
Regina Barragán-Carrillo, Eddy Saad, Renee-Maria Saliby, et al.
European Urology (2024)
Closed Access | Times Cited: 7
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043
Yousef Zakharia, Eric A. Singer, Satwik Acharyya, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Yousef Zakharia, Eric A. Singer, Satwik Acharyya, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Role of metastasectomy in the management of renal cell carcinoma
Mark Mikhail, Kevin Chua, Labeeqa Khizir, et al.
Frontiers in Surgery (2022) Vol. 9
Open Access | Times Cited: 22
Mark Mikhail, Kevin Chua, Labeeqa Khizir, et al.
Frontiers in Surgery (2022) Vol. 9
Open Access | Times Cited: 22
The positive feedback loop between SP1 and MAP2K2 significantly drives resistance to VEGFR inhibitors in clear cell renal cell carcinoma
Zhinan Xia, Zitong Yang, Yu Dong, et al.
International Journal of Biological Sciences (2025) Vol. 21, Iss. 2, pp. 860-873
Open Access
Zhinan Xia, Zitong Yang, Yu Dong, et al.
International Journal of Biological Sciences (2025) Vol. 21, Iss. 2, pp. 860-873
Open Access
Interpretable CT Radiomics-based Machine Learning Model for Preoperative Prediction of Ki-67 Expression in Clear Cell Renal Cell Carcinoma
Yingjie Xv, Bangxin Xiao, Zongjie Wei, et al.
Academic Radiology (2025)
Closed Access
Yingjie Xv, Bangxin Xiao, Zongjie Wei, et al.
Academic Radiology (2025)
Closed Access
Pulmonary Metastasectomy in Renal Cell Carcinoma
Gregory D. Jones, Sudish C. Murthy
Deleted Journal (2025)
Closed Access
Gregory D. Jones, Sudish C. Murthy
Deleted Journal (2025)
Closed Access
Development and validation of prognostic and diagnostic models utilizing immune checkpoint-related genes in public datasets for clear cell renal cell carcinoma
Bin Zhao, Shi Fu, Yuanlong Shi, et al.
Frontiers in Genetics (2025) Vol. 16
Open Access
Bin Zhao, Shi Fu, Yuanlong Shi, et al.
Frontiers in Genetics (2025) Vol. 16
Open Access
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present
Ze Dong, Yue Huang, Wenyang Xia, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Ze Dong, Yue Huang, Wenyang Xia, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
The Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer
Bing Zhong, Jintao Du, Feng Liu, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
Bing Zhong, Jintao Du, Feng Liu, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
Off-label use of first-line immunotherapy for metastatic renal cell carcinoma
Hannah D. McManus, Jessica B. Long, Sarah Westvold, et al.
Clinical Genitourinary Cancer (2025) Vol. 23, Iss. 3, pp. 102330-102330
Closed Access
Hannah D. McManus, Jessica B. Long, Sarah Westvold, et al.
Clinical Genitourinary Cancer (2025) Vol. 23, Iss. 3, pp. 102330-102330
Closed Access
Study on the mechanism of BGN in progression and metastasis of ccRCC
Hanqing Xia, Tianzhen He, Xueyu Li, et al.
BMC Medical Genomics (2025) Vol. 18, Iss. 1
Open Access
Hanqing Xia, Tianzhen He, Xueyu Li, et al.
BMC Medical Genomics (2025) Vol. 18, Iss. 1
Open Access
PRSS53 is a potential novel biomarker related to prognosis and immunity in clear cell renal cell carcinoma
Jiajun Zhang, Guocheng Liu, Wei Wang
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Jiajun Zhang, Guocheng Liu, Wei Wang
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Optimal timing of cytoreductive nephrectomy in metastatic renal cell carcinoma patients considering sarcomatoid status: A real-word study
Ghady Bou‐Nehme Sawaya, Simon Tanguay, Lori Wood, et al.
Clinical Genitourinary Cancer (2025), pp. 102342-102342
Closed Access
Ghady Bou‐Nehme Sawaya, Simon Tanguay, Lori Wood, et al.
Clinical Genitourinary Cancer (2025), pp. 102342-102342
Closed Access
CBX3 promotes clear cell renal carcinoma through PI3K/AKT activation and aberrant immunity
Jiasheng Chen, Yuxin Lin, Shukai Zheng, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Jiasheng Chen, Yuxin Lin, Shukai Zheng, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Novel nanoparticle CS-C60-Fe3O4 magnetically induces tissue-specific aggregation and enhances thermal ablation of hepatocellular carcinoma
Jie Sun, Zhengyao Chang, Xudong Gao, et al.
Cancer Nanotechnology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Jie Sun, Zhengyao Chang, Xudong Gao, et al.
Cancer Nanotechnology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
